Modena Climbs 6% as Firm Eyes Launch of 3 Vaccines
Click to view quick news summary (Spoiler)
Moderna Inc. shares rose over 6% following announcement of pipeline delivery goals, confirming plans to introduce combination flu-COVID, seasonal flu, and norovirus formulations between 2027 and 2028.
Moderna Inc. (MRNA) is one of the 10 Stocks With Standout Gains[cite: 17]. Moderna extended its winning streak to a fourth consecutive day on Tuesday, surging 6.27 percent to close at $55.40 apiece, as investors digested the looming launch of three new vaccines over the next two years[cite: 17]. In a statement on the same day, Moderna Inc. said that it is planning to launch the flu plus COVID, seasonal flu, and norovirus vaccines between 2027 and 2028[cite: 17].
At the same time, it is expecting important clinical milestones this year, including potential pivotal data readouts for its investigational individualized neoantigen therapy (Intismeran autogene) and a therapeutic for the rare genetic disease propionic acidemia, which could support the possible launch of its first oncology and rare disease products[cite: 17].
Corporate Leadership and Market Strategy
In other news, Moderna Inc. appointed Ester Banque as its new chief commercial officer, effective on Monday, June 15[cite: 17]. She is tasked to focus on continuing to build out the company's global commercial organization, leading execution across product launches, and expanding presence in new markets[cite: 17].
Before joining Moderna Inc., Banque served as executive vice president and president for US operations at Zoetis, where she led the company's largest market and was responsible for its US commercial operations, driving growth across key franchises while helping shape the market for future innovation[cite: 17].
While we acknowledge the potential of MRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk[cite: 17]. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock[cite: 17].
